Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy ...
Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...
Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...
The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...
BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...
Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival ...
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...
Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...
The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback